$3.91
8.50% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US68386J2087
Symbol
OPT
Sector
Industry

Opthea Limited - ADR Stock price

$3.91
+0.58 17.42% 1M
+2.05 110.22% 6M
+0.96 32.54% YTD
+0.92 30.77% 1Y
-3.68 48.48% 3Y
-16.91 81.22% 5Y
+2.51 179.29% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.31 8.50%
ISIN
US68386J2087
Symbol
OPT
Sector
Industry

Key metrics

Market capitalization $601.77m
Enterprise Value $629.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4,845.62
P/S ratio (TTM) P/S ratio 4,629.00
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 15.94%
Revenue (TTM) Revenue $130.00k
EBIT (operating result TTM) EBIT $-192.66m
Free Cash Flow (TTM) Free Cash Flow $-160.97m
EPS (TTM) EPS $-2.67
P/S forward 59.70
EV/Sales forward 62.49
Short interest 0.06%
Show more

Is Opthea Limited - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Opthea Limited - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Opthea Limited - ADR forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Opthea Limited - ADR forecast:

Buy
100%

Financial data from Opthea Limited - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
0.13 0.13
18% 18%
100%
- Direct Costs 0.10 0.10
-
77%
0.02 0.02
-
15%
- Selling and Administrative Expenses 16 16
44% 44%
12,031%
- Research and Development Expense 177 177
46% 46%
136,108%
-193 -193
-
-148,123%
- Depreciation and Amortization 0.10 0.10
-
77%
EBIT (Operating Income) EBIT -193 -193
29% 29%
-148,203%
Net Profit -221 -221
56% 56%
-169,946%

In millions USD.

Don't miss a Thing! We will send you all news about Opthea Limited - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Opthea Limited - ADR Stock News

Neutral
GlobeNewsWire
10 days ago
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly ...
Neutral
GlobeNewsWire
about one month ago
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral pre...
Neutral
GlobeNewsWire
about one month ago
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and pro...
More Opthea Limited - ADR News

Company Profile

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Head office Australia
CEO Frédéric Guerard
Founded 1984
Website www.opthea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today